Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Neumora Therapeutics, Inc. (NMRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NMRA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.05
1 Year Target Price $6.05
| 1 | Strong Buy |
| 2 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.75% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 255.87M USD | Price to earnings Ratio - | 1Y Target Price 6.05 |
Price to earnings Ratio - | 1Y Target Price 6.05 | ||
Volume (30-day avg) 8 | Beta - | 52 Weeks Range 0.61 - 17.19 | Updated Date 08/15/2025 |
52 Weeks Range 0.61 - 17.19 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.57 |
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.45 | Actual -0.33 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.63% | Return on Equity (TTM) -89.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 58246774 | Price to Sales(TTM) - |
Enterprise Value 58246774 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.65 | Shares Outstanding 161944992 | Shares Floating 86062658 |
Shares Outstanding 161944992 | Shares Floating 86062658 | ||
Percent Insiders 27.53 | Percent Institutions 56.98 |
Upturn AI SWOT
Neumora Therapeutics, Inc.
Company Overview
History and Background
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2019. It focuses on developing novel therapeutics for brain diseases and disorders. It went public in September 2023.
Core Business Areas
- Neurology: Development of treatments for neurological disorders such as epilepsy and neuropathic pain.
- Psychiatry: Development of treatments for psychiatric disorders such as major depressive disorder (MDD) and schizophrenia.
Leadership and Structure
Paul L. Berns serves as Chairman and CEO. The company operates with a functional structure, led by a team of experienced pharmaceutical executives and scientists.
Top Products and Market Share
Key Offerings
- Navacaprant (NMRA-140): An oral kappa opioid receptor (KOR) antagonist being developed for the treatment of major depressive disorder (MDD). Currently in Phase 3 clinical trials. Market share is currently 0% due to lack of FDA approval. Competitors include SSRIs, SNRIs, and other antidepressants from companies like Eli Lilly (LLY), Pfizer (PFE), and Johnson & Johnson (JNJ).
- NMRA-511: A selective vasopressin 1A receptor (V1AR) antagonist for the treatment of social anxiety disorder (SAD). Currently in Phase 2 clinical trials. Market share is currently 0% due to lack of FDA approval. Competitors include SSRIs, SNRIs and Benzodiazepines.
- NMRA-985: A MOR antagonist for the treatment of Schizophrenia. Currently in Phase 1 clinical trials. Market share is currently 0% due to lack of FDA approval. Competitors include antipsychotics from companies like Otsuka and Janssen.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and stringent regulatory requirements. The market for brain disease therapeutics is large and growing, driven by aging populations and increased awareness of mental health disorders.
Positioning
Neumora is positioned as a company focused on innovative treatments for underserved neurological and psychiatric conditions, with a pipeline of novel drug candidates. Its competitive advantage lies in its approach to target specific brain pathways implicated in these disorders.
Total Addressable Market (TAM)
The total addressable market for neuropsychiatric drugs is estimated to be over $100 billion. Neumora aims to capture a significant share of this market with its pipeline of novel therapies. Their TAM can be as large as 5% of the market in any individual therapy they are effective in.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting validated pathways
- Experienced management team
- Strong financial backing
- Proprietary precision medicine platform
Weaknesses
- Early stage clinical development
- High R&D costs
- Reliance on clinical trial success
- Limited revenue stream currently
Opportunities
- Significant unmet need in brain disease therapeutics
- Potential for strategic partnerships
- Expansion of pipeline through internal discovery or acquisition
- Advancements in precision medicine to improve patient outcomes
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent expiration
Competitors and Market Share
Key Competitors
- LLY
- PFE
- JNJ
- ALKS
- VRAY
Competitive Landscape
Neumora competes with large pharmaceutical companies and other biotech companies developing treatments for brain diseases. Its competitive advantage lies in its novel targets and precision medicine approach, but faces challenges related to clinical trial risk and regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Limited historical data due to recent IPO. Growth depends on successful clinical trial results.
Future Projections: Future growth is projected based on the advancement of its pipeline and potential regulatory approvals. Analyst estimates vary depending on clinical trial outcomes.
Recent Initiatives: Focus on advancing Navacaprant (NMRA-140) into Phase 3 trials and progressing other pipeline candidates through clinical development.
Summary
Neumora Therapeutics is a clinical-stage biopharmaceutical company with a focus on developing novel treatments for brain diseases. It has a promising pipeline of drug candidates, but its success depends on the outcome of clinical trials. The company faces competition from larger, more established pharmaceutical companies and must navigate significant regulatory hurdles. The financial position is secure based on recent reports, but there is no guarantee on product performance. Future success is reliant on Phase 3 approvals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Neumora Therapeutics, Inc. SEC Filings (e.g., 10-K, 10-Q), Company Website, Analyst Reports, ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on available information and may be subject to change. Investing in biotech companies involves significant risks, including the risk of clinical trial failure and regulatory setbacks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neumora Therapeutics, Inc.
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2023-09-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 96 | Website https://www.neumoratx.com |
Full time employees 96 | Website https://www.neumoratx.com | ||
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.